Pub Date : 2022-04-20DOI: 10.2174/1871529X22666220420112735
T. Hariyanto, Joshua Edward Hananto, D. Intan, A. Kurniawan
BACKGROUND Hypertension and heart failure are known risk factors for coronavirus disease 2019 (COVID-19) severity and mortality outcomes. Beta-blocker is one of the drugs of choice to treat these conditions. The purpose of this study is to explore the relationship between pre-admission beta-blocker use and COVID-19 outcomes. METHODS PubMed and Europe PMC were used as the database for our search strategy by using combined keywords related to our aims until December 10th, 2020. All articles related to COVID-19 and beta-blocker were retrieved. Review Manager 5.4 and Comprehensive Meta-Analysis 3 software were used to perform statistical analysis. RESULTS A total of 43 studies consisting of 11,388,556 patients were included in our analysis. Our meta-analysis showed that the use of beta-blocker was associated with increased risk of COVID-19 [OR 1.32 (95% CI 1.02 - 1.70), p = 0.03, I2 = 99%, random-effect modelling], clinical progression [OR 1.37 (95% CI 1.01 - 1.88), p = 0.04, I2 = 89%, random-effect modelling], and mortality from COVID-19 [OR 1.64 (95% CI 1.22 - 2.19), p = 0.0009, I2 = 94%, random-effect modelling]. Meta-regression showed that the association with mortality outcome were influenced by age (p = 0.018) and hypertension (p = 0.005). CONCLUSIONS The risk and benefits of using beta-blocker as a drug of choice to treat hypertensive patients should be put into account and reviewed individually case by case, knowing their association in higher incidence and severity of Covid-19 infections. Other first-line antihypertensive drugs may be considered as an alternative therapy if the risk of administering beta blockers outweigh the benefits in Covid-19 infection.
背景:高血压和心力衰竭是2019冠状病毒病(COVID-19)严重程度和死亡率结果的已知危险因素。受体阻滞剂是治疗这些疾病的首选药物之一。本研究的目的是探讨入院前β受体阻滞剂使用与COVID-19结局之间的关系。方法使用spubmed和Europe PMC作为数据库，结合我们目标的关键词进行搜索策略，截止到2020年12月10日。检索所有与COVID-19和β -受体阻滞剂相关的文章。采用Review Manager 5.4和Comprehensive Meta-Analysis 3软件进行统计分析。结果共纳入43项研究，11,388,556例患者。我们的荟萃分析显示，β受体阻滞剂的使用与COVID-19的风险增加[OR 1.32 (95% CI 1.02 - 1.70)， p = 0.03, I2 = 99%，随机效应模型]、临床进展[OR 1.37 (95% CI 1.01 - 1.88)， p = 0.04, I2 = 89%，随机效应模型]和COVID-19的死亡率[OR 1.64 (95% CI 1.22 - 2.19)， p = 0.0009, I2 = 94%，随机效应模型]相关。meta回归结果显示，年龄(p = 0.018)和高血压(p = 0.005)影响与死亡率结局的相关性。结论乙型受体阻滞剂作为治疗高血压患者的首选药物，应考虑其风险和获益，并逐案评估，了解其与Covid-19感染的高发病率和严重程度的关系。如果在Covid-19感染中使用受体阻滞剂的风险超过益处，则可以考虑使用其他一线降压药物作为替代疗法。
{"title":"Pre-admission beta-blocker therapy and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.","authors":"T. Hariyanto, Joshua Edward Hananto, D. Intan, A. Kurniawan","doi":"10.2174/1871529X22666220420112735","DOIUrl":"https://doi.org/10.2174/1871529X22666220420112735","url":null,"abstract":"BACKGROUND\u0000Hypertension and heart failure are known risk factors for coronavirus disease 2019 (COVID-19) severity and mortality outcomes. Beta-blocker is one of the drugs of choice to treat these conditions. The purpose of this study is to explore the relationship between pre-admission beta-blocker use and COVID-19 outcomes.\u0000\u0000\u0000METHODS\u0000PubMed and Europe PMC were used as the database for our search strategy by using combined keywords related to our aims until December 10th, 2020. All articles related to COVID-19 and beta-blocker were retrieved. Review Manager 5.4 and Comprehensive Meta-Analysis 3 software were used to perform statistical analysis.\u0000\u0000\u0000RESULTS\u0000A total of 43 studies consisting of 11,388,556 patients were included in our analysis. Our meta-analysis showed that the use of beta-blocker was associated with increased risk of COVID-19 [OR 1.32 (95% CI 1.02 - 1.70), p = 0.03, I2 = 99%, random-effect modelling], clinical progression [OR 1.37 (95% CI 1.01 - 1.88), p = 0.04, I2 = 89%, random-effect modelling], and mortality from COVID-19 [OR 1.64 (95% CI 1.22 - 2.19), p = 0.0009, I2 = 94%, random-effect modelling]. Meta-regression showed that the association with mortality outcome were influenced by age (p = 0.018) and hypertension (p = 0.005).\u0000\u0000\u0000CONCLUSIONS\u0000The risk and benefits of using beta-blocker as a drug of choice to treat hypertensive patients should be put into account and reviewed individually case by case, knowing their association in higher incidence and severity of Covid-19 infections. Other first-line antihypertensive drugs may be considered as an alternative therapy if the risk of administering beta blockers outweigh the benefits in Covid-19 infection.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91369874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Direct oral anticoagulants (DOACs) carry a lower potential risk of food/herb and drug interactions compared with oral vitamin K antagonists. However, as a new class of medications, drug interactions of DOACs have not been fully known.
Case presentation: We herein present the case of a 64-year old male with the complaint of acute onset epistaxis and bleeding gums following the concomitant use of rivaroxaban and saffron supplement. It seems that coadministration of DOACs and saffron supplements should be avoided due to the potential drug-herbal interactions and possible risk of subsequent bleeding complications.
Conclusion: However, further larger scale surveillance studies are needed to confirm the findings and assess the clinical significance.
背景：与口服维生素 K 拮抗剂相比，直接口服抗凝剂（DOAC）发生食物/草药和药物相互作用的潜在风险较低。然而，作为一类新药，DOACs 的药物相互作用尚未完全为人所知：我们在此介绍一例 64 岁男性患者的病例，患者主诉在同时服用利伐沙班和藏红花补充剂后出现急性鼻衄和牙龈出血。由于潜在的药物与草药之间的相互作用以及随后可能出现出血并发症的风险，似乎应避免同时服用 DOACs 和藏红花补充剂：然而，还需要进一步开展更大规模的监测研究，以确认研究结果并评估其临床意义。
{"title":"Bleeding Complication in a Patient with Concomitant Use of Rivaroxaban and Saffron Supplement: a Case Report.","authors":"Zinat Heidari, Maryam Daei, Hossein Khalili, Amirhossein Sahebkar","doi":"10.2174/1871529X22666220418102545","DOIUrl":"https://doi.org/10.2174/1871529X22666220418102545","url":null,"abstract":"<p><strong>Background: </strong>Direct oral anticoagulants (DOACs) carry a lower potential risk of food/herb and drug interactions compared with oral vitamin K antagonists. However, as a new class of medications, drug interactions of DOACs have not been fully known.</p><p><strong>Case presentation: </strong>We herein present the case of a 64-year old male with the complaint of acute onset epistaxis and bleeding gums following the concomitant use of rivaroxaban and saffron supplement. It seems that coadministration of DOACs and saffron supplements should be avoided due to the potential drug-herbal interactions and possible risk of subsequent bleeding complications.</p><p><strong>Conclusion: </strong>However, further larger scale surveillance studies are needed to confirm the findings and assess the clinical significance.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139907056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-31DOI: 10.2174/1871529x2104211231145446
A. Carella
Since 2008, Professor Dr. Fabian Kiessling has been leading the Institute of Experimental Molecular Imaging at the Helmholtz Institute for Biomedical Engineering at the RWTH-University in Aachen, Germany. The aim of his research is the development of novel diagnostic, theranostic and therapeutic probes as well as of advanced imaging technologies and image analysis tools. In this context, the main focus of his research is the investigation and diagnostic assessment of vascular and microenvironmental tissue properties and the exploration of its impact on disease progression and therapy response. Fabian Kiessling studied Medicine and did his thesis at the University in Heidelberg, Germany. Until the end of 2002, he worked as resident in the Department of Radiology at the German Cancer Research Center (DKFZ) in Heidelberg. In 2003, he moved to the Department of Medical Physics in Radiology of the DKFZ as leader of the Molecular Imaging group. In parallel, he did his clinical training at different departments of the University of Heidelberg and received the board certification as Radiologist in 2007. Fabian Kiessling did his habilitation in experimental radiology in 2006. In 2008, he founded the invivoContrast GmbH together with Matthias Braeutigam. Fabian Kiessling is author of more than 400 scientific publications and book chapters, has edited four books and received many research awards, among those are the “Emil Salzer Price for Cancer Research” and the “Richtzenhain Price”. Furthermore, he was awarded as Fellow of the World Molecular Imaging Society in 2019 and in 2020 was identified as “Highly Cited Researcher” by Clarivate Analytics (Web of Science). He is founding member of the European Society for Functional and Molecular Imaging in Radiology (ESMOFIR), has served as treasurer and secretary of the European Society for Molecular Imaging (ESMI), is founding member of the ESMI working group “Image Guided Therapy and Drug Delivery (IGTDD)”, and was chairman of the “Molecular Imaging” subcommittee of the European Society for Radiology (ESR). In addition, he is a member of the Board of Trustees of the World Molecular Imaging Society and was Program Chair of the World Molecular Imaging Conference (WMIS) in New York in 2016.
自2008年以来，Fabian Kiessling教授一直领导德国亚琛工业大学Helmholtz生物医学工程研究所实验分子成像研究所。他的研究目标是开发新的诊断、治疗和治疗探针，以及先进的成像技术和图像分析工具。在此背景下，他的主要研究重点是血管和微环境组织特性的调查和诊断评估，以及探索其对疾病进展和治疗反应的影响。法比安·基斯林在德国海德堡大学学习医学，并完成了他的论文。直到2002年底，他一直在海德堡的德国癌症研究中心(DKFZ)放射科担任住院医师。2003年，他转到DKFZ放射医学物理系，担任分子成像组组长。同时，他在海德堡大学的不同部门接受了临床培训，并于2007年获得了委员会的放射科医师认证。2006年，法比安·基斯林(Fabian Kiessling)在实验放射学中进行了康复治疗。2008年，他与Matthias Braeutigam共同创立了invvivocontrast GmbH。费边·基斯林是400多篇科学出版物和书籍章节的作者，编辑了四本书，并获得了许多研究奖项，其中包括“埃米尔·萨尔泽癌症研究奖”和“里奇赞海恩奖”。此外，他于2019年被授予世界分子成像学会会员，并于2020年被Clarivate Analytics (Web of Science)确定为“高被引研究员”。他是欧洲放射学功能和分子成像学会(ESMOFIR)的创始成员，曾担任欧洲分子成像学会(ESMI)的财务主管和秘书，是ESMI“图像引导治疗和药物输送(IGTDD)”工作组的创始成员，并担任欧洲放射学会(ESR)“分子成像”小组委员会主席。此外，他还是世界分子成像学会董事会成员，并于2016年在纽约担任世界分子成像会议(WMIS)的项目主席。
{"title":"Meet the Editorial Board Member","authors":"A. Carella","doi":"10.2174/1871529x2104211231145446","DOIUrl":"https://doi.org/10.2174/1871529x2104211231145446","url":null,"abstract":"Since 2008, Professor Dr. Fabian Kiessling has been leading the Institute of Experimental Molecular Imaging at the Helmholtz Institute for Biomedical Engineering at the RWTH-University in Aachen, Germany. The aim of his research is the development of novel diagnostic, theranostic and therapeutic probes as well as of advanced imaging technologies and image analysis tools. In this context, the main focus of his research is the investigation and diagnostic assessment of vascular and microenvironmental tissue properties and the exploration of its impact on disease progression and therapy response. Fabian Kiessling studied Medicine and did his thesis at the University in Heidelberg, Germany. Until the end of 2002, he worked as resident in the Department of Radiology at the German Cancer Research Center (DKFZ) in Heidelberg. In 2003, he moved to the Department of Medical Physics in Radiology of the DKFZ as leader of the Molecular Imaging group. In parallel, he did his clinical training at different departments of the University of Heidelberg and received the board certification as Radiologist in 2007. Fabian Kiessling did his habilitation in experimental radiology in 2006. In 2008, he founded the invivoContrast GmbH together with Matthias Braeutigam. Fabian Kiessling is author of more than 400 scientific publications and book chapters, has edited four books and received many research awards, among those are the “Emil Salzer Price for Cancer Research” and the “Richtzenhain Price”. Furthermore, he was awarded as Fellow of the World Molecular Imaging Society in 2019 and in 2020 was identified as “Highly Cited Researcher” by Clarivate Analytics (Web of Science). He is founding member of the European Society for Functional and Molecular Imaging in Radiology (ESMOFIR), has served as treasurer and secretary of the European Society for Molecular Imaging (ESMI), is founding member of the ESMI working group “Image Guided Therapy and Drug Delivery (IGTDD)”, and was chairman of the “Molecular Imaging” subcommittee of the European Society for Radiology (ESR). In addition, he is a member of the Board of Trustees of the World Molecular Imaging Society and was Program Chair of the World Molecular Imaging Conference (WMIS) in New York in 2016.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74785648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-18DOI: 10.21203/rs.3.rs-579040/v1
M. Daei, H. Khalili, Zinat Heidari
BACKGROUND Direct oral anticoagulants (DOACs) carry a lower potential risk of food/herb and drug interactions compared with oral vitamin K antagonists. However, as a new class of medications, drug interactions of DOACs have not been fully known. CASE PRESENTATION We herein present the case of a 64-year old male with the complaint of acute onset epistaxis and bleeding gums following the concomitant use of rivaroxaban and saffron supplement. It seems that coadministration of DOACs and saffron supplements should be avoided due to the potential drug-herbal interactions and possible risk of subsequent bleeding complications. CONCLUSION However, further larger scale surveillance studies are needed to confirm the findings and assess the clinical significance.
{"title":"Bleeding Complication in a Patient with Concomitant Use of Rivaroxaban and Saffron Supplement: a Case Report.","authors":"M. Daei, H. Khalili, Zinat Heidari","doi":"10.21203/rs.3.rs-579040/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-579040/v1","url":null,"abstract":"BACKGROUND Direct oral anticoagulants (DOACs) carry a lower potential risk of food/herb and drug interactions compared with oral vitamin K antagonists. However, as a new class of medications, drug interactions of DOACs have not been fully known. CASE PRESENTATION We herein present the case of a 64-year old male with the complaint of acute onset epistaxis and bleeding gums following the concomitant use of rivaroxaban and saffron supplement. It seems that coadministration of DOACs and saffron supplements should be avoided due to the potential drug-herbal interactions and possible risk of subsequent bleeding complications. CONCLUSION However, further larger scale surveillance studies are needed to confirm the findings and assess the clinical significance.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84468524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-01DOI: 10.2174/1871529X19666190912152041
Beihua Zhong, Shuangtao Ma, Donna H. Wang
Background Activation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV1) channels protects the heart from Ischemia/Reperfusion (I/R) injury through releasing Calcitonin Gene-Related Peptide (CGRP) and Substance P (SP). The current study aimed to study the cardioprotective effects of TRPV1 in obesity. Methods TRPV1 gene knockout (TRPV1-/-) and Wild-Type (WT) mice were Fed a High-Fat Diet (HFD) or a control diet or for 20 weeks, and then the hearts were collected for I/R injury ex vivo. The hearts were mounted on a Langendorff apparatus and subjected to ischemia (30 min) and reperfusion (40 min) after incubated with capsaicin (10 nmol/L), CGRP (0.1 µmol/L) and SP (0.1 µmol/L). Then, Coronary Flow (CF), left ventricular peak positive dP/dt (+dP/dt), Left Ventricular Developed Pressure (LVDP) and Left Ventricular End-Diastolic Pressure (LVEDP) were measured. Results HFD intake remarkably reduced CF, +dP/dt and LVDP and elevated LVEDP in both strains (P<0.05). Treatment with capsaicin decreased infarct size, increased CF, +dP/dt and LVDP, and decreased LVEDP in WT mice on control diet (P<0.05), but did not do so in other three groups. Treatment with CGRP and SP decreased infarct size in both strains fed with control diet (P<0.05). In contrast, not all the parameters of cardiac postischemic recovery in HFD-fed WT and TRPV1-/- mice were improved by CGRP and SP. Conclusion These results suggest that HFD intake impairs cardiac postischemic recovery. HFD-induced impairment of recovery is alleviated by CGRP in both strains and by SP only in TRPV1-/- mice, indicating that the effects of CGRP and SP are differentially regulated during HFD intake.
{"title":"Protective Effects of TRPV1 Activation Against Cardiac Ischemia/Reperfusion Injury is Blunted by Diet-Induced Obesity","authors":"Beihua Zhong, Shuangtao Ma, Donna H. Wang","doi":"10.2174/1871529X19666190912152041","DOIUrl":"https://doi.org/10.2174/1871529X19666190912152041","url":null,"abstract":"Background Activation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV1) channels protects the heart from Ischemia/Reperfusion (I/R) injury through releasing Calcitonin Gene-Related Peptide (CGRP) and Substance P (SP). The current study aimed to study the cardioprotective effects of TRPV1 in obesity. Methods TRPV1 gene knockout (TRPV1-/-) and Wild-Type (WT) mice were Fed a High-Fat Diet (HFD) or a control diet or for 20 weeks, and then the hearts were collected for I/R injury ex vivo. The hearts were mounted on a Langendorff apparatus and subjected to ischemia (30 min) and reperfusion (40 min) after incubated with capsaicin (10 nmol/L), CGRP (0.1 µmol/L) and SP (0.1 µmol/L). Then, Coronary Flow (CF), left ventricular peak positive dP/dt (+dP/dt), Left Ventricular Developed Pressure (LVDP) and Left Ventricular End-Diastolic Pressure (LVEDP) were measured. Results HFD intake remarkably reduced CF, +dP/dt and LVDP and elevated LVEDP in both strains (P<0.05). Treatment with capsaicin decreased infarct size, increased CF, +dP/dt and LVDP, and decreased LVEDP in WT mice on control diet (P<0.05), but did not do so in other three groups. Treatment with CGRP and SP decreased infarct size in both strains fed with control diet (P<0.05). In contrast, not all the parameters of cardiac postischemic recovery in HFD-fed WT and TRPV1-/- mice were improved by CGRP and SP. Conclusion These results suggest that HFD intake impairs cardiac postischemic recovery. HFD-induced impairment of recovery is alleviated by CGRP in both strains and by SP only in TRPV1-/- mice, indicating that the effects of CGRP and SP are differentially regulated during HFD intake.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"13 1","pages":"122 - 130"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79648103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-31DOI: 10.2174/1871529X19666190918141859
Fatemeh Sayyadipour, N. Amirizadeh, A. Oodi, Masoud Khalili, Fakhredin Saba
Aims Factor VIII (FVIII) replacement therapy remains a primary treatment for hemophilia A, however, the development of FVIII antibodies (inhibitors) and short half-life of the FVIII products are the major complications. Erythrocytes may prevent rapid removal of drugs from plasma. Erythrocytes are biocompatible and non-immunogenic drug delivery. In this study, in vitro activity of FVIII encapsulated by human erythrocytes was investigated. Methods FVIII was loaded into erythrocytes using the hypo-osmotic dialysis technique. FVIII activity assay has been analyzed using Activated Partial Thromboplastin Time (APTT). Presence of FVIII on erythrocytes was detected by western blotting and flowcytometry using specific monoclonal antibody (abcam, U.K) against FVIII. Moreover, the osmotic fragility and hematologic parameters of FVIII-loaded carrier erythrocytes were measured. Results Our results indicated that FVIII could not cross the membrane, where plenty of FVIII was found on the surface of the carrier erythrocyte. Flow cytometery results showed that 11% of the loaded carrier erythrocytes was positive for FVIII protein on their surface. The greatest activation of FVIII in both groups including lysate and non-lysate FVIII-loaded RBCs was observed on the first day, and the coagulant activity of this factor was gradually reduced on days 3 and 5. In 1:50 dilution of both groups, significant differences in FVIII activity were observed in 1:50 dilution of both groups, especially on the 5th day. Conclusion This study aims to introduce erythrocytes as appropriate carriers for FVIII to prolong the dosing intervals in the effective and safe levels for a relatively longer time.
{"title":"Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII","authors":"Fatemeh Sayyadipour, N. Amirizadeh, A. Oodi, Masoud Khalili, Fakhredin Saba","doi":"10.2174/1871529X19666190918141859","DOIUrl":"https://doi.org/10.2174/1871529X19666190918141859","url":null,"abstract":"Aims Factor VIII (FVIII) replacement therapy remains a primary treatment for hemophilia A, however, the development of FVIII antibodies (inhibitors) and short half-life of the FVIII products are the major complications. Erythrocytes may prevent rapid removal of drugs from plasma. Erythrocytes are biocompatible and non-immunogenic drug delivery. In this study, in vitro activity of FVIII encapsulated by human erythrocytes was investigated. Methods FVIII was loaded into erythrocytes using the hypo-osmotic dialysis technique. FVIII activity assay has been analyzed using Activated Partial Thromboplastin Time (APTT). Presence of FVIII on erythrocytes was detected by western blotting and flowcytometry using specific monoclonal antibody (abcam, U.K) against FVIII. Moreover, the osmotic fragility and hematologic parameters of FVIII-loaded carrier erythrocytes were measured. Results Our results indicated that FVIII could not cross the membrane, where plenty of FVIII was found on the surface of the carrier erythrocyte. Flow cytometery results showed that 11% of the loaded carrier erythrocytes was positive for FVIII protein on their surface. The greatest activation of FVIII in both groups including lysate and non-lysate FVIII-loaded RBCs was observed on the first day, and the coagulant activity of this factor was gradually reduced on days 3 and 5. In 1:50 dilution of both groups, significant differences in FVIII activity were observed in 1:50 dilution of both groups, especially on the 5th day. Conclusion This study aims to introduce erythrocytes as appropriate carriers for FVIII to prolong the dosing intervals in the effective and safe levels for a relatively longer time.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":"24 1","pages":"131 - 137"},"PeriodicalIF":0.0,"publicationDate":"2020-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88503928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：